產品簡介:精神分裂症 - 在成熟市場中開拓出新利基市場的輔助療法

產品簡介:精神分裂症 - 在成熟市場中開拓出新利基市場的輔助療法 是由出版商Datamonitor在2011年10月所出版的。 這份英文市場調查報告書包含Pages: 193 價格從美金11400起跳。

簡介

本報告提供精神分裂症的治療藥物市場相關調查，主要上市產品、開發管道產品的簡介、開發概要、臨床資料、SWOT分析、產品定位、臨床、商業性魅力相關分析，為您概述為以下內容。

摘要整理

概要

市場定義·概要

• 產品概要

上市產品簡介

• Zyprexa/Zyprexa Relprevv (olanzapine; Eli Lilly)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Abilify (aripiprazole; Bristol-Myers Squibb/大塚製藥)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Seroquel/Seroquel XR (quetiapine; AstraZeneca)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Latuda (lurasidone; Sunovion Pharmaceuticals/大日本住友製藥/武田藥品工業)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Invega/Invega Sustenna (paliperidone; Johnson & Johnson)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Saphris (asenapine; Merck & Co.)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Fanapt (iloperidone; Novartis/Vanda)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Risperdal/Risperdal Consta (risperidone; Johnson & Johnson)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Geodon (ziprasidone; Pfizer)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• 其他精神分裂症用的上市產品

開發中產品簡介

• RG1678 (RO4917838; Roche/中外製藥)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Vyvanse (lisdexamfetamine; Shire)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• Pimavanserin tartrate (ACP-103; Acadia Pharmaceuticals)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• BL-1020 (formerly CYP-1020; BioLineRx)
  • 製藥簡介
  • 發展概要
  • SWOT分析
  • 產品定位
  • 臨床及商業性魅力
• 其他

目錄

Description

Introduction

With the imminent loss of market exclusivity of key atypical antipsychotics Zyprexa (olanzapine; Eli Lilly) and Seroquel (quetiapine: AstraZeneca), schizophrenia pipeline therapies will launch into a competitive market. Datamonitor views the development of novel drugs and adjunctive therapies as an important strategy for success.

Features and benefits

• Access Datamonitor's assessment of key marketed and pipeline drugs' clinical and commercial attractiveness.
• Assessment of the strengths, weaknesses, opportunities and threats for marketed and late-stage pipeline candidates
• Analysis of the product positioning for each marketed agents within the schizophrenia market.
• Evaluate the latest clinical trial data for late-stage pipeline drugs and how they satisfy the unmet needs in schizophrenia

Highlights

• In order to thrive in the schizophrenia environment, new therapies must be sufficiently differentiated from existing antipsychotics. Datamonitor believes developers of undifferentiated oral products will struggle to compete in this mature market because but will find position as second or later line of therapy for treatment refractory patients
• Developing depot formulations is a key successful life-cycle management strategy in the schizophrenia market in order to protect franchises from generic erosion. Recent launches of monthly depots Zyprexa Relprevv and Invega Sustenna have helped Eli Lilly and Johnson & Johnson strengthen their position in this market.
• The prospects for adjunctive therapies for hard-to-treat schizophrenia symptoms will be highly welcomed and will create a new niche in this mature market. Rather than compete with existing therapies, these drugs will complement generic formulations to partially combat generic erosion.

Your key questions answered

• Where will new adjunctive therapies be positioned?
• What strategies will developers implement upon generic erosion of their brands?
• Where will the new pipeline therapies fit into the treatment algorithm?
• What are the comparative strengths and weaknesses of the key schizophrenia brands and how do they compare to and pipeline candidates?

TOC

Executive Summary

• Strategic scoping and focus
• Datamonitor key findings

OVERVIEW

• Catalyst
• Summary

MARKET DEFINITION AND OVERVIEW

• Product overview

MARKETED PRODUCT PROFILES

• Zyprexa/Zyprexa Relprevv (olanzapine; Eli Lilly)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Seroquel/Seroquel XR (quetiapine; AstraZeneca)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Latuda (lurasidone; Sunovion Pharmaceuticals/Dainippon Sumitomo/Takeda)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Invega/Invega Sustenna (paliperidone; Johnson & Johnson)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Saphris (asenapine; Merck & Co.)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Fanapt (iloperidone; Novartis/Vanda)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Risperdal/Risperdal Consta (risperidone; Johnson & Johnson)
• Drug overview
• Development overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Geodon (ziprasidone; Pfizer)
• Drug overview
• Developmental overview
• SWOT analysis
• Product positioning
• Clinical and commercial attractiveness
• Other marketed drugs for schizophrenia
• Clozaril/Leponex (clozapine; Novartis)
• Lonasen (blonanserin; Dainippon Sumitomo)

PIPELINE PRODUCT PROFILES: MONOTHERAPIES

• Abilify depot (aripiprazole long-acting injection; Bristol-Myers Squibb/Otsuka Pharmaceuticals)
• Drug overview
• Development overview
• Product positioning
• SWOT analysis
• Satisfaction of unmet needs
• Clinical and commercial attractiveness
• Adasuve (Staccato loxapine; Alexza Pharmaceuticals)
• Drug profile
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Cariprazine (Forest Laboratories/Mitsubishi Tanabe/Gedeon Richter)
• Drug overview
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• LY2140023 (Eli Lilly)
• Drug overview
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Zicronapine (Lu 31-130; Lundbeck)
• Drug overview
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Other monotherapies in development
• OPC-34712 (Otsuka)

PIPELINE PRODUCT PROFILES: ADJUNCTIVE THERAPIES

• RG1678 (RO4917838; Roche/Chugai)
• Drug profile
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Vyvanse (lisdexamfetamine; Shire)
• Drug profile
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Pimavanserin tartrate (ACP-103; Acadia Pharmaceuticals)
• Drug overview
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• BL-1020 (formerly CYP-1020; BioLineRx)
• Drug overview
• Development overview
• Satisfaction of unmet needs
• SWOT analysis
• Clinical and commercial attractiveness
• Othe

相關商品

精神病相關市場調查報告書

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年04月

精神醫學相關的各種合作契約：契約條件・合意內容
Psychiatry Partnering Terms and Agreements
價格 : US $ 2695
出版日期 : 2012年03月

R&D趨勢:憂鬱症 - 成熟市場下逐漸減少的治療藥物
R&D Trends: Depression - Clinical attrition driven by mature market conditions
價格 : US $ 3800
出版日期 : 2012年01月

Datamonitor發行的製藥相關市場調查報告書

美國及EU主要5個國家的HIV藥市場:市場預測

HIV Market Forecast

價格 : US $ 11400

出版日期 : 2012年02月

市場及產品預測:HIV - 患病人口的擴大與新STR劇增的歐美銷售

Market and Product Forecasts: HIV - Rising prevalence and novel STRs boost sales in the US and Europe

價格 : US $ 11400

出版日期 : 2012年02月

FDA的Bydureon的認證:醫生的見解

Bydureon FDA Approval: Physician Opinion

價格 : US $ 3800

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!